drugset / Trial / NCT03199339
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
RandomizedSequentialSingle-blindTreatment
Summary
The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects
Timeline
- Start
- 2017-08-29
- Primary completion
- 2018-07-08
- Completion
- 2018-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupropion | Small molecule | 150 mg | — |
| Comparator | Midazolam | Small molecule | 2 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 100 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 200 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 250 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 400 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 500 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 1000 mg | Oral |
| Comparator | TBA-7371 | Small molecule | 1500 mg | Oral |